| Drug Earnings Deluge http://www.cnbc.com/id/2136... Diabetes Articles CNBC - CNBC’s Mike Huckman said Pfizer’s “bombshell” announcement that it will cease selling its once-promising inhalable insulin product Exubera took down a number of stocks in the diabetes care industry, including Lilly, Alkermes (ALKS) , MannKind ... |
| V.A. Is Limiting Use of Diabetes Drug http://www.nytimes.com/2007... Diabetes Articles New York Times - The Department of Veterans Affairs has decided to severely limit the use of Avandia , the once-popular drug for Type 2 diabetes , delivering another blow to the product’s maker, GlaxoSmithKline . The decision by the V.A. is likely to further reduce ... |
| Pfizer's Profit Plunges on Failed Diabetes Drug Costs (Update5) http://www.bloomberg.com/ap... Diabetes Articles Bloomberg - Oct. 18 (Bloomberg) -- Pfizer Inc., the world's largest drugmaker, said third-quarter profit fell 77 percent on costs for discontinuing its inhaled insulin treatment Exubera. Pfizer said today it wrote off $2.8 billion to abandon Exubera, which didn ... |
| Rite Aid and dLife Partner to Educate and Support Diabetes Community http://www.forbes.com/prnew... Diabetes Articles Forbes - WESTPORT, Conn., Oct. 18 /PRNewswire/ -- Rite Aid has announced the launch of a 360 degrees/365 Day Diabetes Alliance with dLife, the only integrated multimedia education platform solely for the diabetes community. There are an estimated 20.8 million ... |
| American Diabetes Association, Reps. Castle, Space, and DeGette to ... http://www.forbes.com/prnew... Diabetes Articles Forbes - Congressmen Castle and Space, and ADA volunteers to recap August experience at October 25 briefing in Rayburn The American Diabetes Association (ADA), in conjunction with members of the Congressional Diabetes Caucus and CVS Pharmacy, will host a ... |
| Pfizer 3Q Profit Falls on Exubera Charge http://www.forbes.com/feeds... Diabetes Articles Forbes - Sales of diabetes drug Exubera have been disappointing for both the company and Wall Street since its launch. The company said it will return licensing rights to partner Nektar Therapeutics (nasdaq: NKTR - news - people ) Inc. and ... |
| Aspreva, Husky, Moly Mines, Prizm, QLT: Canada Equity Preview http://www.bloomberg.com/ap... Diabetes Articles Bloomberg - The drugmaker said in a CNW statement that final results of Phase I/II multiple-dose trials of Exendin-4 show that the treatment for Type 2 diabetes was ``well tolerated'' and ``effective in lowering blood glucose'' if taken in the tested dosages ... |
| Pfizer tumbles on diabetes drug flop http://www.ft.com/cms/s/6e2... Diabetes Articles Financial Times - Pfizer , the world’s largest drugmaker, said third quarter net income fell 77 per cent because of a $2.8bn charge from abandoning Exubera, its diabetes drug, and increased competition from generic medicines. Net earnings were $761m, down from $3 ... |
| Pfizer's Profit Plunges on Write-Off of Diabetes Drug (Update2) http://www.bloomberg.com/ap... Diabetes Articles Bloomberg - Oct. 18 (Bloomberg) -- Pfizer Inc., the world's largest drugmaker, said third-quarter profit fell 77 percent on costs for discontinuing the diabetes treatment Exubera and on competition from cheaper copies of its best-selling drugs. Pfizer abandoned ... |
| Pfizer Earnings Fall 77%, Hurt by Insulin Drug Exit http://www.cnbc.com/id/2134... Diabetes Articles CNBC - New York-based Pfizer said it would return its worldwide Exubera rights to Nektar and work with doctors over the next three months to switch Exubera patients to other diabetes treatments. After being launched, many investors assumed Exubera would ... |